Ardelyx Inc.'s (ARDX) phase III clinical trial of Tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis has met its primary endpoint and was generally well-tolerated.
from RTT - Biotech http://ift.tt/2lkZK1i
via IFTTT
No comments:
Post a Comment